Clinical Trial Update: Modulating ApoE Signalling to Reduce Brain Inflammation, deLirium and postopErative Cognitive Dysfunction [Phase 2]

View source ↗

Summary

Phase 2 trial update investigating an ApoE signaling–modulating therapy to reduce brain inflammation, postoperative delirium, and postoperative cognitive dysfun…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postoperative Cognitive Dysfunction
• Postoperative Delirium

Drugs mentioned

• ApoE signaling modulator (investigational)

Snippet

Sponsor: Miles Berger, MD PhD | Conditions: Postoperative Delirium, Postoperative Cognitive Dysfunction | Phase 2 | Status: COMPLETED | Results posted: 2024-09-04